-
Durability and tolerability of first-line regimens including two nucleoside
reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir
or -darunavir: data from the ICONA Cohort<sup/>.
d'Arminio Monforte A, Lorenzini P, et al
HIV
Clin Trials. 2018 Mar
1:1-9.
Abstract
-
FULL-TEXT ARTICLE
Impact of the HIV-1 genetic background and HIV-1 population size on the
evolution of raltegravir resistance.
Fun A, Leitner T, Vandekerckhove L,
Retrovirology.
2018 Jan 5;15(1):1.
Paper
-
Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir
and rilpivirine in both female and male genital fluids from HIV-positive
patients receiving regimens containing these antiretrovirals.
Lê MP, Belarbi L, Chaix ML, Dulioust E, et al
J Antimicrob Chemother. 2017
Sep 8.
Abstract
-
Plasma trough concentrations of darunavir/ritonavir and
raltegravir in older patients with HIV-1 infection.
Calza L, Colangeli V, Magistrelli E, et
al
HIV Med. 2017 Jan 24.
Abstract
-
Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-,
Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
Kelesidis T, Moser C, Stein JH,
J Infect Dis. 2016 Sep
1;214(5):748-52
Abstract
-
Brief Report: High Peak Level of Plasma Raltegravir Concentration
in Patients With ABCB1 and ABCG2 Genetic Variants.
Tsuchiya K, Hayashida T, Hamada A,
et al
J Acquir Immune Defic Syndr.
2016 May 1;72(1):11-4.
Abstract
-
A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early
Human Immunodeficiency Virus Infection: Challenges and Lessons Learned.
Collier AC, Chun TW, Maenza J, et al
Biores Open Access. 2016 Jan 1;5(1):15-21.
Abstract
-
Reduced raltegravir clearance in HIV-infected liver transplant recipients: an
unexpected interaction with immunosuppressive therapy?
Cattaneo D, Puoti M, Sollima S,
et al
J Antimicrob Chemother. 2016 Jan
10
Abstract.
-
Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct
subphases (1a and 1b).
Andrade A, Guedj J, Rosenkranz SL, et al
AIDS. 2015 Nov
28;29(18):2419-26.
Abstract.
-
Evaluación de Costo Efectividad de Dolutegravir (dtg) Vs Raltegravir (Ral) En
Segunda Línea de Tratamiento en Pacientes Con Vih en Colombia.
Velandia D, Gomez JM, Vivas S.
Value Health. 2015
Nov;18(7):A871.
Abstract.
-
Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
Gutierrez-Valencia A, Chacón-Mora N, Ruiz-Valderas R, et al
Medicine (Baltimore). 2015
Oct;94(43):e1743.
Abstract.
-
Long-term immunologic and virologic responses on raltegravir-containing regimens
among ART-experienced participants in the HIV Outpatient Study.
Buchacz K, Wiegand R, Armon C, et al
HIV Clin Trials. 2015
Aug;16(4):139-46
Abstract.
-
Correlation between UGT1A1 polymorphisms and raltegravir plasma trough
concentrations in Japanese HIV-1-infected patients.
Yagura H, Watanabe D, Ashida M,
J Infect Chemother.
2015 Jul 6
Abstract
-
Relationship Between Genital Drug Concentrations and Cervical
Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a
Raltegravir Versus a Boosted Atazanavir Regimen.
Meditz AL, Palmer C, Predhomme J,et
al
AIDS Res Hum Retroviruses. 2015 Jun 10.
Abstract
-
Comparison of the Metabolic Effects of Ritonavir boosted Darunavir or
Atazanavir versus Raltegravir, and the Impact of Ritonavir Plasma Exposure:
ACTG 5257.
Ofotokun I, Na LH, Landovitz RJ, et al
Clin Infect Dis. 2015 Mar 12.
Abstract
-
Raltegravir use prospectively assessed in a major HIV outpatient clinic in
Italy: sample population, virological-immunological activity, and
tolerability profile.
Manfredi R, Calza L, Marinacci G, et al
Infez Med.
2014 Dec 1;22(4):288-95.
Abstract
-
Association between first-year virological response to raltegravir and
long-term outcomes in treatment-experienced patients with HIV-1 infection.
Eron JJ, Cooper DA, Steigbigel RT, et al
Antivir Ther. 2014 Oct 27.
Abstract
-
HIV-1 group O integrase displays lower enzymatic efficiency and higher
susceptibility to raltegravir than HIV-1 group M subtype B integrase.
Depatureaux A, Quashie PK, Mesplède T, et al
Antimicrob Agents Chemother.
2014 Sep 15
Abstract
-
A multisystem investigation of raltegravir association with
intestinal tissue: implications for pre-exposure prophylaxis and
eradication.
Moss DM, Curley P, Shone A,
J Antimicrob Chemother.
2014 Aug 11.
Abstract
-
Rate and determinants of residual viremia in
multidrug-experienced patients successfully treated with
raltegravir-based regimens.
Baroncelli S, Pirillo MF, Galluzzo CM, et al
AIDS Res Hum Retroviruses.
2014 Aug 5
Abstract
-
Lack of mitochondrial toxicity of darunavir,
raltegravir and rilpivirine in neurons and hepatocytes: a
comparison with efavirenz.
Blas-García A, Polo M, Alegre F,
et al
J Antimicrob Chemother.
2014 Jul 9
Abstract
-
4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds
Having High Potency against Raltegravir-Resistant Integrase
Mutants of HIV-1.
Zhao XZ, Smith SJ, Métifiot M, et al
J Med Chem. 2014 Jun 16.
Abstract
-
In vitro analysis of the susceptibility of HIV-1
subtype A and CRF01_AE integrases to raltegravir.
Bellecave P, Malato L, Calmels C, et al
Int J Antimicrob Agents.
2014 Jun 2.
Abstract
-
Low Raltegravir Concentration in Cerebrospinal
Fluid in Patients with ABCG2 Genetic Variants.
Tsuchiya K, Hayashida T, Hamada A, et al
J Acquir Immune Defic Syndr.
2014 May 27
Abstract
FULL-TEXT ARTICLE
Reduction of the HIV Protease Inhibitor-Induced ER Stress and
Inflammatory Response by Raltegravir in Macrophages.
Zhang X, Cao R, Liu R, et al
PLoS One. 2014 Mar 13;9(3):e90856.
Paper
-
Raltegravir monohydrate.
Yamuna TS, Jasinski JP, Anderson BJ, et al
Acta Crystallogr Sect E Struct Rep Online.
2013 Nov 6;69(Pt 12):o1743-4.
Abstract
-
Role of P-glycoprotein in the efflux of
raltegravir from human intestinal cells and CD4+ T-cells as an
interaction target for anti-HIV agents.
Hashiguchi Y, Hamada A, Shinohara T, et al
Biochem Biophys Res Commun.
2013 Aug 24.
Abstract
-
High interpatient variability of raltegravir CSF
concentrations in HIV-positive patients: a pharmacogenetic
analysis.
Calcagno A, Cusato J, Simiele M, et al
J Antimicrob Chemother.
2013 Aug 23.
Abstract
-
In-vitro phenotypic suscept 1 'non b' integrase
inhibitors naive clinical isolates to dolutegravir and
raltegravir.
Charpentier C, Bertine M, Visseaux B, et al
AIDS.
2013 Aug 12.
Abstract
-
Reduced HIV-1 integrase flexibility as a
mechanism for raltegravir resistance.
Dewdney TG, Wang Y, Kovari IA, et al
J Struct Biol. 2013 Jul
24.
Abstract
-
Differential penetration of raltegravir
throughout gastrointestinal tissue: implications for eradication
and cure.
Patterson KB, Prince HA, Stevens T, et al
AIDS. 2013 Jun
1;27(9):1413-9.
Abstract
-
Raltegravir flexibility and its impact on
recognition by the HIV-1 IN targets.
Arora R, de Beauchene IC, Polanski J, et al
J Mol Recognit.
2013 Sep;26(9):383-401
Abstract
-
Determination of P-glycoprotein surface
expression and functional ability after in vitro treatment with
darunavir or raltegravir in lymphocytes of healthy donors.
Tempestilli M, Gentilotti E, Tommasi C, et al
Int Immunopharmacol. 2013 May 23
Abstract
-
Predicting intestinal absorption of raltegravir
using a population-based ADME simulation.
Moss DM, Siccardi M, Back DJ, Owen A.
J Antimicrob Chemother. 2013 Mar 20.
Abstract
-
FULL-TEXT
ARTICLE
Role of Baseline HIV-1 DNA Level in Highly-Experienced Patients
Receiving Raltegravir, Etravirine and Darunavir/Ritonavir
Regimen (ANRS139 TRIO Trial).
Charpentier C, Fagard C, Colin C, et al
PLoS One.
2013;8(1):e53621.
Paper
-
Test for CCR5 tropism and treatment with
maraviroc in Sicily: an observational retrospective multicentre
study.
Celesia B, Gussio M, Franco
A, et al
J Int AIDS Soc. 2012 Nov
11;15(6):18216
Abstract
-
Lack of correlation between UGT1A1*6, *28
genotypes, and plasma raltegravir concentrations in Japanese
HIV-1-infected patients.
Takahashi M, Hirano A, Oishi Y, et al
J Int AIDS Soc. 2012 Nov
11;15(6):18342.
Abstract
-
No evidence of autoimmune disorders in
antiretroviral-experienced HIV-1-infected subjects after
long-term treatment with raltegravir.
Baroncelli S, Mezzaroma I, Fantauzzi A,
et al
Antivir Ther.
2012 Oct 9.
Abstract
-
FULL-TEXT ARTICLE
Prolonged and Substantial Discordance in Prevalence of
Raltegravir-Resistant HIV-1 in Plasma versus PBMC Samples
Revealed by 454 "Deep" Sequencing.
Lee GQ, Swenson LC, Poon AF,
et al
PLoS One.
2012;7(9):e46181.
Paper
-
FULL-TEXT
ARTICLE
Unprocessed Viral DNA Could Be the Primary Target of the HIV-1
Integrase Inhibitor Raltegravir.
Ammar FF, Abdel-Azeim S, et
al
PLoS One.
2012;7(7):e40223.
Paper
-
Role of Raltegravir in HIV-1 Management.
Rokas KE, Bookstaver PB, Shamroe CL,
et al
Ann Pharmacother. 2012
Apr;46(4):578-89.
Abstract
-
Divalent metals and pH alter raltegravir disposition in vitro.
Moss DM, Siccardi M, Murphy M, et al
Antimicrob Agents Chemother.
2012 Mar 26.
Abstract
-
Novel agents for the treatment of HIV-2
infection.
Peterson K, Rowland-Jones S.
Antivir Ther. 2012 Jan
25.
Abstract
-
Diketoacid Inhibitors of HIV-1 Integrase: From
L-708,906 to Raltegravir and Beyond.
Beare KD, Coster MJ, Rutledge PJ.
Curr Med Chem. 2012 Jan
2.
Abstract
-
Rural Residence and Adoption of a Novel HIV
Therapy in a National, Equal-Access Healthcare System.
Ohl M, Lund B, Belperio PS, et
al
AIDS Behav. 2011 Dec 29
Abstract
-
Lack of correlation between UGT1A1*6, *28 genotypes, and plasma
raltegravir concentrations in Japanese
HIV-1-infected patients.
Hirano A, Ikemura K, Takahashi M,
et al
AIDS Res Hum Retroviruses.
2011 Oct 7
Abstract
-
Effect of raltegravir on the total and
unintegrated proviral HIV DNA during raltegravir-based HAART.
Nicastri E, Tommasi C, Abbate I, et al
Antivir Ther.
2011;16(6):797-803.
Abstract
-
FULL-TEXT ARTICLE
Rapid Turnover of 2-LTR HIV-1 DNA during Early Stage of Highly
Active Antiretroviral Therapy.
Zhu W, Jiao Y, Lei R, et al
PLoS One.
2011;6(6):e21081
Paper
-
Dynamics of HIV-1 DNA level in highly antiretroviral-experienced
patients receiving raltegravir-based
therapy.
Charpentier C, Piketty C, Laureillard D,
et
al
Eur J Clin Microbiol Infect Dis.
2011 May 11.
Abstract
-
Cell disposition of raltegravir and newer antiretrovirals in
HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
Fayet Mello A, Buclin T, Franc C, et al
J Antimicrob Chemother.
2011 Apr 19.
Abstract
-
Raltegravir Concentrations in the Genital Tract of HIV-1
infected Women Treated with a
raltegravir containing Regimen : DIVA 01 study
Clavel C, Peytavin G, Tubiana R,
et al
Antimicrob Agents Chemother.
2011 Mar 28.
Abstract
-
Raltegravir: the first HIV-1 integrase strand
transfer inhibitor in the HIV armamentarium.
Nguyen BY, Isaacs RD, Teppler H, et al
Ann N Y Acad Sci. 2011
Mar;1222(1):83-9.
Abstract
-
Liver tolerance of raltegravir-containing
antiretroviral therapy in HIV-infected patients with chronic
hepatitis C.
Macías J, Neukam K, Portilla J, Iribarren JA, et al
J Antimicrob Chemother.
2011 Mar 10
Abstract
-
Raltegravir use in special populations.
Johnson M.
Eur J Med Res.
2009 Nov 24;14 Suppl 3:43-6.
Abstract
-
Dynamic Escape of Pre-Existing
Raltegravir-Resistant HIV-1 from Raltegravir Selection Pressure.
Codoñer FM, Pou C, Thielen A, et al
Antiviral Res.
2010 Sep 27
Abstract
-
Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed
the 50% Inhibitory Concentration for
Wild-Type HIV-1.
Croteau D, Letendre S, Best BM, et al
Antimicrob Agents Chemother.
2010 Sep 27
Abstract
-
Comparison of the influence of four classes of HIV antiretrovirals on
adipogenic
differentiation: the minimal effect of raltegravir and atazanavir.
Minami R, Yamamoto M, Takahama S,
et al
J Infect Chemother.
2010 Aug 13.
Abstract
-
The Effect of Raltegravir Intensification on Low-level Residual
Viremia in HIV-Infected Patients on
Antiretroviral Therapy: A Randomized Controlled Trial.
Gandhi RT, Zheng L, Bosch RJ, et al
PLoS Med.
2010 Aug 10;7(8
Abstract
-
Time course of total HIV-1 DNA and 2-long-terminal repeat
circles in patients with controlled
plasma viremia switching to a raltegravir-containing regimen.
Delaugerre C, Charreau I, Braun J,
et al
AIDS.
2010 Jul 30.
Abstract
-
Postprandial lipid effects of low-dose ritonavir
vs. raltegravir in HIV-uninfected adults.
Samaras K, Richardson R, Carr A.
AIDS. 2010 Jul
17;24(11):1727-31
Abstract
-
Prevention of HIV Protease Inhibitor-induced Dysregulation of Hepatic
Lipid
Metabolism by Raltegravir via ER stress Signaling Pathways.
Cao R, Hu Y, Wang Y, Gurley EC, et al
|
J Pharmacol Exp Ther.
2010 May 14
Abstract
-
FULL-TEXT ARTICLE
Raltegravir is a potent inhibitor of XMRV, a virus implicated in
prostate cancer and
chronic fatigue syndrome.
Singh IR, Gorzynski JE, Drobysheva D, et al
PLoS One. 2010 Apr
1;5(4):e9948.
Paper
-
FULL-TEXT PDF ARTICLE
Response of a simian immunodeficiency virus (SIVmac251) to
raltegravir: a basis
for a new treatment for simian AIDS and an animal model for
studying lentiviral
persistence during antiretroviral therapy.
Lewis MG, Norelli S, Collins M, et al
Retrovirology.
2010 Mar 16;7(1):21
Paper
|
-
Effect of metal-cation antacids on the pharmacokinetics of
1200 mg raltegravir.
Krishna R, East L, Larson P, Valiathan C,
et al
J Pharm Pharmacol.
2016 Nov;68(11):1359-1365. d
Abstract
-
.Raltegravir Pharmacokinetics in Patients on
Asunaprevir-Daclatasvir.
Barrail-Tran A, Vincent C, Furlan V,. et al
Antimicrob Agents Chemother.
2015 Dec;59(12):7903-7905.
Abstract
-
Pharmacokinetic drug-drug interaction study
between raltegravir and citalopram.
Blonk MI, Langemeijer CC, Colbers AP, et al
Antivir Ther. 2015 Sep 16.
Abstract
-
Pharmacokinetic and pharmacodynamic evaluation of raltegravir and
experience from clinical trials in HIV-positive patients.
Calcagno A, D'Avolio A, Bonora S.
Expert Opin Drug Metab Toxicol. 2015
Jul;11(7):1167-76.
Abstract
-
Effect of HIV-infection and menopause status on raltegravir
pharmacokinetics in the blood and genital tract.
Cottrell ML, Patterson KB, Prince HM,
et al
Antivir Ther.
2015 Jun 3.
Abstract
-
Pharmacokinetic Determinants of Virological Response to
Raltegravir in the In vitro Pharmacodynamic Hollow Fiber
Infection Model (HFIM) System.
Brown AN, Adams JR, Baluya DL, Drusano GL.
Antimicrob Agents Chemother.
2015 Apr 13. pii: AAC.00469-15.
Abstract
-
The pharmacokinetic profile of
raltegravir-containing antiretroviral therapy in
HIV-infected individuals over 60 years of age.
Vera JH, Jackson A, Dickinson L, et
al
HIV Clin Trials.
2015 Jan-Feb;16(1):39-42.
Abstract
-
FULL-TEXT ARTICLE
Pharmacokinetics of chewed vs. swallowed raltegravir in
a patient with AIDS and MAI infection: some new
conflicting data.
Spinner CD, Wille F, Schwerdtfeger C,
et al
AIDS Res Ther.
2015 Jan 17;12(1):
Paper
-
Comparison of the pharmacokinetics of
raltegravir given at two doses of 400 mg by swallowing
versus one dose of 800 mg by chewing in healthy
volunteers: a randomized, open-label, two-period, single
dose, cross-over phase 1 study.
Cattaneo D, Cossu MV, Fucile S, et al
Ther Drug Monit. 2014
Jul 1.
Abstract
-
Pharmacokinetics of raltegravir in the
semen of HIV-infected men.
Antoniou T, Loutfy MR, Brunetta J, et al
Antivir Ther.
2014 Feb 12.
Abstract
-
Raltegravir pharmacokinetics in
HIV/HCV-coinfected patients with advanced liver
cirrhosis (Child-Pugh C).
Hernández-Novoa B, Moreno A, Pérez-Elías MJ, et al
J Antimicrob Chemother. 2014
Feb;69(2):471-5.
Abstract
FULL-TEXT ARTICLE
Genetic and non-genetic determinants of raltegravir penetration into
cerebrospinal fluid: a single arm pharmacokinetic study.
Johnson DH, Sutherland D, Acosta EP, et al
PLoS One. 2013 Dec
11;8(12):e82672.
Paper
-
Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with
advanced liver cirrhosis (Child-Pugh C).
Hernández-Novoa B, Moreno A, Pérez-Elías MJ, et al
J Antimicrob Chemother. 2013 Oct 4
Abstract
-
Pharmacokinetic Study of Dual Therapy With Raltegravir 400 mg
Twice Daily and Darunavir/Ritonavir 800/100 mg Once Daily in HIV-1-Infected
Patients.
Martínez-Rebollar M, Muñoz A, Pérez I, et al
Ther Drug Monit. 2013 Aug;35(4):552-6.
Abstract
-
Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected
patients.
Jansen A, Colbers E, van der Ven A, et al
HIV Med.
2013 Mar 18.
Abstract
-
Pharmacokinetics of Maraviroc, Raltegravir, Darunavir,
and Etravirine in the Semen of HIV-Infected Men.
Antoniou T, Hasan S, Loutfy MR, et al
J Acquir Immune Defic Syndr.
2013 Feb 1;62(2):e58-60.
Abstract
-
Raltegravir Pharmacokinetics in Treatment-Naive
Patients is not influenced by Race: Results from the Raltegravir Early
Therapy in African-Americans Living with HIV (REAL) Study.
Wohl DA, Dumond JB, Blevins S, et al
Antimicrob Agents Chemother. 2012 Nov
26
Abstract
-
Comparison of the in vivo pharmacokinetics and in vitro dissolution of
raltegravir in HIV patients receiving
the drug by swallowing or by chewing.
Cattaneo D, Baldelli S, Cerea M, et al
Antimicrob Agents Chemother.
2012 Sep 10.
Abstract
-
Pharmacokinetics and Pharmacodynamics of Once-Daily
Versus Twice-Daily Raltegravir in Treatment-Naive
HIV-Infected Patients.
Rizk ML, Hang Y, Luo WL,
et al
Antimicrob Agents Chemother.
2012 Mar 19.
Abstract
Population Pharmacokinetic Analysis and Pharmacogenetics of
Raltegravir In HIV-positive a
d Healthy Individuals.
Arab-Alameddine M, Fayet-Mello A, Lubomirov R,
et al
Antimicrob Agents Chemother.
2012 Feb 27
Abstract
-
Pharmacokinetic and short-term virologic response of low dose raltegravir
400mg once daily maintenance
therapy.
Ananworanich J, Gorowara M, Avihingsanon A, et al
Antimicrob Agents Chemother.
2012 Jan 17
Abstract
-
Inter- and intra-patient variability of raltegravir
pharmacokinetics in HIV-1-infected subjects.
Cattaneo D, Gervasoni C, Meraviglia P,
et al
J Antimicrob Chemother. 2011 Nov 29
Abstract
-
Pharmacokinetic Effects of Co-Administration of Lersivirine with Raltegravir
or Maraviroc
in Healthy Subjects.
Vourvahis M, Langdon G, Labadie RR, et al
Antimicrob Agents Chemother. 2011 Nov
28
Abstract
-
Pharmacokinetic Modeling of Plasma and Intracellular
Concentrations of Raltegravir in Healthy Volunteers.
Wang L, Soon GH, Seng KY,
et al
Antimicrob Agents Chemother.
2011 Jul 11
Abstract
-
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.
Calcagno A, Nozza S, Bonora S,
et
al
J Antimicrob Chemother.
2011 Jun 4
Abstract
-
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in
treatment experienced
patients.
Barrail-Tran A, Yazdanpanah Y, Goldwirt L, et al
AIDS.
2010 Oct 23;24(16):2581-3.
Abstract
-
Effect of Antacids on the Pharmacokinetics of Raltegravir in Human
Immunodeficiency Virus
Seronegative Volunteers.
Kiser JJ, Bumpass JB, Meditz AL, et al
Antimicrob Agents Chemother.
2010 Oct 4.
Abstract
-
Pharmacokinetics and Pharmacogenomics of Once Daily Raltegravir and
Atazanavir in
Healthy Volunteers.
Neely M, Decosterd L, Fayet A, et al
Antimicrob Agents Chemother. 2010 Sep
Abstract
-
Raltegravir: a review of its pharmacokinetics,
pharmacology and clinical studies.
Burger DM.
Expert Opin Drug Metab Toxicol.
2010 Aug 12.
Abstract
-
Assessment of the pharmacokinetics of co-administered
maraviroc and raltegravir.
Andrews E, Glue P, Fang J,
et al
Br J Clin Pharmacol.
2010 Jan;69(1):51-57.
Abstract
-
Pharmacokinetics of Raltegravir in Individuals With UGT1A1
Polymorphisms.
Wenning L, Petry A, Kost J, et al
Clin Pharmacol Ther.
2009 Mar 11
Abstract
-
Lack of a Clinically Important Effect of Moderate
Hepatic Insufficiency and Severe Renal Insufficiency on
Raltegravir Pharmacokinetics.
Iwamoto M, Hanley WD, Petry AS, et al
Antimicrob Agents Chemother.
2009 Feb 17
Abstract
-
Antiretroviral Activity, Pharmacokinetics, and Tolerability of
MK-0518, a Novel Inhibitor of
HIV-1 Integrase,
Dosed As Monotherapy for 10 Days in Treatment-Naive
HIV-1-Infected
Individuals.
Markowitz M, Morales-Ramirez JO, Nguyen BY, et al
J Acquir Immune Defic
Syndr. 2006 Dec 15;43(5):509-515.
Abstract
-
Pharmacokinetics and interactions of raltegravir
Placeres Alsina MM, Tuset Creus M, Miró JM.
Enferm Infecc Microbiol Clin.
2008 Nov;26 Suppl 12:23-
Abstract
-
Safety of raltegravir-based antiretroviral therapy in
HIV-infected patients receiving multi-kinase inhibitors.
Loulergue P, Merad M, Coriat R,
Invest
New Drugs.
2016 Nov 12
Abstract
-
Safety analysis of raltegravir/truvada regimen in HIV/HCV
co-infected patients without switchback after HCV treatment.
Ehret R, Walter H, Ingiliz P, et al
J Int AIDS Soc.
2014 Nov 2;17(4 Suppl 3):1964
Abstract
-
Hepatic safety and tolerability of
raltegravir among HIV patients coinfected with hepatitis B
and/or C.
Hurt CB, Napravnik S, Moore RD, Eron JJ Jr.
Antivir Ther. 2014 Jan 23.
Abstract
-
Raltegravir can be used safely in
HIV-1-infected patients treated with warfarin.
Honda H, Gatanaga H, Aoki T, et al.
Int J STD AIDS. 2012
Dec;23(12):903-4.
Abstract
-
A randomized study of pharmacokinetics, efficacy and
safety of two raltegravir plus atazanavir strategies in
ART-treated adults.
Carey D, Pett SL, Bloch M,
et al
J Acquir Immune Defic Syndr.
2012 Mar 14.
Abstract
-
Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in
Vertically HIV-Infected Children, Adolescents and Young Adults: A
60-Month Follow-Up Study.
Viganò A, Bedogni G, Manfredini V,
et al
Clin Drug Investig.
2011;31(6):407-15
Abstract
-
Long-Term Safety from the Raltegravir Clinical
Development Program.
Teppler H, Brown DD,
Leavitt RY,
et al
Curr HIV Res.
2011 Jan 3.
Abstract
-
Hepatic safety profile of raltegravir in HIV-infected
patients with chronic hepatitis C.
Vispo E, Mena A, Maida I, et al
J Antimicrob Chemother.
2009 Dec 23
Abstract
-
Atazanavir increases the plasma concentrations of 1200 mg
raltegravir dose
Krishna R, East L, Larson P, V
Biopharm Drug Dispos.
2016 Sep 30.
Abstract -
Predictive factors of clinically significant
drug-drug interactions among regimens based on protease
inhibitors, non-nucleoside reverse transcriptase inhibitors
and raltegravir
Cervero M, Torres R, Jusdado JJ,
et al
Med Clin (Barc).
2016 Mar 10.
Abstract-
Raltegravir pharmacokinetics in patients on
asunaprevir/daclatasvir (ANRS HC 30 QUADRIH).
Barrail-Tran A, Vincent C, Furlan V,
et al
Antimicrob Agents Chemother.
2015 Oct 5.
Abstract -
Pharmacokinetic Drug-Drug Interaction Study
Between Raltegravir and Atorvastatin 20 mg in Healthy
Volunteers.
Blonk M, van Beek M, Colbers A, et al
J Acquir Immune Defic Syndr.
2015 May 1;69(1):44-51.
Abstract -
Effect of faldaprevir on raltegravir pharmacokinetics in
healthy volunteers.
Joseph D, Rose P, Strelkowa N, et al
J Clin Pharmacol.
2014 Oct 28.
Abstract -
No pharmacokinetic interaction between raltegravir and
amlodipine: importance for co-prescribing in ageing
HIV-infected individuals.
Singh GJ, Jackson A, D'Avolio A,
et al
AIDS.
2014 Aug 24;28(13):1993-5.
Abstract -
Effect of intermittent rifampicin on the pharmacokinetics
and safety of raltegravir.
Reynolds HE, Chrdle A, Egan D, et al
J Antimicrob Chemother. 2014 Sep 26. pii: dku376
Abstract -
Pharmacokinetic interaction of rifapentine
and raltegravir in healthy volunteers.
Weiner M, Egelund EF, Engle M, et al
J Antimicrob Chemother.
2013 Dec 15
Abstract -
Raltegravir has a low propensity to cause
clinical drug interactions through inhibition of major drug
transporters: an in vitro evaluation.
Rizk ML, Houle R, Chan GH, et al
Antimicrob Agents Chemother.
2013 Dec 2
Abstract -
Raltegravir can be used safely in
HIV-1-infected patients treated with warfarin.
Honda H, Gatanaga H, Aoki T, et al.
Int J STD AIDS.
2012 Dec;23(12):903-4.
Abstract -
Elevated liver enzymes resulting from an
interaction between Raltegravir and Panax ginseng: a case
report and brief review.
Mateo-Carrasco H, Gálvez-Contreras MC, Fernández-Ginés FD,
Nguyen TV.
Drug Metabol Drug Interact. 2012;27(3):17
Abstract -
Raltegravir dosage adjustment in HIV-infected
patients receiving etravirine.
Do VT, Higginson RT, Fulco PP.
Am J Health Syst Pharm.
2011 Nov 1;68(21):2049-54
Abstract -
Pharmacokinetic Effects of Co-Administration of Lersivirine with
Raltegravir or Maraviroc
in Healthy Subjects.
Vourvahis M, Langdon G, Labadie RR, et al
Antimicrob Agents Chemother. 2011
Nov 28
Abstract -
Raltegravir dosage adjustment in HIV-infected patients
receiving etravirine.
Do VT, Higginson RT, Fulco PP.
Am J Health Syst Pharm. 2011 Nov 1
Abstract -
Effect of raltegravir on estradiol and norgestimate
plasma pharmacokinetics following oral contraceptive
administration in healthy women.
Anderson MS, Hanley WD, Moreau AR,
et
al
Br J Clin Pharmacol. 2011
Apr;71(4):616-20.
Abstract -
Pharmacokinetic and safety profile of raltegravir and
ribavirin, when dosed separately and together, in healthy volunteers.
Ashby J, Garvey L, Erlwein OW,
et
al
J Antimicrob Chemother. 2011
Mar 15.
Abstract -
Pharmacokinetics and safety of the co-administration of
the antiretroviral raltegravir
and the lipid-lowering drug ezetimibe in healthy volunteers.
Jackson A, D'Avolio A, Watson V
et al
J Antimicrob Chemother. 2011
Apr;66(4):885-9.
Abstract -
Predictors of Clinically Significant Drug-Drug Interactions Among
Patients Treated with Nonnucleoside
Reverse Transcriptase Inhibitor-, Protease Inhibitor-, and
Raltegravir-Based Antiretroviral Regimens (March).
Patel N, Abdelsayed S, Veve M, Miller CD.
Ann Pharmacother. 2011 Mar 8.
Abstract -
Raltegravir is a substrate for SLC22A6: A putative
mechanism for the interaction between
raltegravir and tenofovir.
Moss DM, Kwan WS, Liptrott NJ,
et al
Antimicrob Agents Chemother.
2010 Nov
Abstract -
Lack of a Clinically Meaningful Pharmacokinetic Effect of Rifabutin on
Raltegravir:
In Vitro/In Vivo Correlation.
Brainard DM, Kassahun K, Wenning LA, et al
J Clin Pharmacol.
2010 Sep 17.
Abstract -
Daily dosing of tacrolimus in patients treated with HIV-1 therapy
containing a
ritonavir-boosted protease inhibitor or raltegravir.
Bickel M, Anadol E, Vogel M, et al
J Antimicrob Chemother.
2010 Mar
Abstract -
Assessment of the pharmacokinetics of co-administered
maraviroc and raltegravir.
Andrews E, Glue P, Fang J,
et al
Br J Clin Pharmacol.
2010 Jan;69(1):51-57.
Abstract -
Effect of Rifampin, a Potent Inducer of Drug
Metabolizing Enzymes, on the
Pharmacokinetics of Raltegravir.
Wenning LA, Hanley WD, Brainard DM, et
al
Antimicrob Agents Chemother. 2009 May 11-13
Abstract -
Effect of Tipranavir + Ritonavir on Pharmacokinetics of Raltegravir.
Hanley WD, Wenning LA, Moreau A
Antimicrob Agents Chemother.
2009 Apr 27
Abstract -
Effects of Omeprazole on Plasma Levels of Raltegravir.
Iwamoto M, Wenning LA,
Nguyen BY, et al
Clin Infect Dis. 2009 Jan 1.
Abstract-
Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of
Raltegravir.
Iwamoto M, Wenning LA, Petry AS, et al
Antimicrob Agents Chemother. 2008 Oct 6
Abstract-
Minimal Pharmacokinetic Interaction Between the HIV Non-Nucleoside
Reverse Transcriptase Inhibitor
Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects.
Anderson MS, Kakuda TN, Hanley W, et al
Antimicrob Agents Chemother. 2008 Oct 6.
Abstract-
Lack of a significant drug interaction between raltegravir and tenofovir.
Wenning LA, Friedman EJ, Kost JT, et al
Antimicrob Agents Chemother. 2008 Jul 14.
Abstract -
Atazanavir modestly increases plasma levels of raltegravir in
healthy subjects.
Iwamoto M, Wenning LA, Mistry GC, et al
Clin Infect Dis. 2008 Jul 1;47(1):137-40
Abstract-
Lack of a pharmacokinetic effect of raltegravir on midazolam: in
vitro/in vivo correlation.
Iwamoto M, Kassahun K, Troyer MD, et al
J Clin Pharmacol. 2008 Feb;48(2):209-14.
Abstract
-
First line raltegravir/emtricitabine/tenofovir combination
in HIV-2
infection: phase 2 non-comparative trial (ANRS 159 HIV-2).
Matheron S, Descamps D, Gallien S,
et a
lClin
Infect Dis.
2018 Mar 24.
Abstract -
Virologic suppression and CD4 cell count
recovery after initiation of raltegravir- or efavirenz-
containing HIV treatment regimens.
Edwards JK, Cole SR, Hall HI, et al
AIDS.
2017 Nov 2 -
Efficacy of raltegravir, etravirine and darunavir/ritonavir
for treatment-experienced HIV patients from a non-urban
clinic population in the United States.
Ebers AM, Alkabab Y, Wispelwey B, et al
Ther Adv Infect Dis.
2017 Sep;4(5):
Abstract -
Efficacy and safety of nucleoside-sparing regimen based on
raltegravir and ritonavir-boosted darunavir in
HIV-1-infected treatment-experienced patients".
Jabłonowska E, Pulik P, Kalinowska A, et al
J Med Virol.
2017 Apr 8.
Abstract -
Total cellular HIV-1 DNA decreases after switching to
raltegravir-based regimens in patients with suppressed HIV-1
RNA.
Rossetti B, Meini G, Bianco C, et ak
J Clin Virol. 2017
Mar 23
Abstract -
Efficacy of raltegravir-containing regimens in
antiretroviral-naïve and -experienced individuals in routine
clinical practice.
Jaeckle M, Khaykin P, Haberl A,
Int J STD AIDS.
2016 Nov;27(13):1170-1179.
Abstract -
Different impact of raltegravir versus efavirenz on CD4/CD8
ratio recovery in HIV-infected patients.
Serrano-Villar S, Zhou Y, Rodgers AJ, Moreno S.
J Antimicrob Chemother.
2016 Sep 21
Abstract -
FULL-TEXT ARTICLE
A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in
Early Human Immunodeficiency Virus Infection: Challenges and Lessons
Learned.
Collier AC, Chun TW, Maenza J, et al
Biores Open Access. 2016 Jan 1;5(1):15-21.
Paper-
Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed
HIV-1-Infected Patients on Antiretroviral Therapy Including a
Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse
Transcriptase Inhibitors.
Calza L, Danese I, Magistrelli E,
et al
HIV Clin Trials.
2016 Jan 5:1-10.
Abstract -
Efficacy of Raltegravir-containing regimens in antiretroviral-naïve and
-experienced individuals in routine clinical practice.
Jaeckle M, Khaykin P, Haberl A,
et al
Int J STD AIDS.
2015 Oct 1
Abstract -
Transcriptional Changes in CD8+ T Cells During
Antiretroviral Therapy Intensified With Raltegravir.
Ouyang Z, Buzon MJ, Zheng L, et al
Open Forum Infect Dis.
2015 Apr 1;2(2):ofv045.
Abstract -
Effects of raltegravir combined with tenofovir/emtricitabine on body shape, bone
density, and lipids in African-Americans initiating HIV therapy.
Young L, Wohl DA, Hyslop WB, et
al
HIV Clin Trials.
2015 Aug 7:1945577115Y0000000002.
Abstract -
Long-term immunologic and virologic responses on raltegravir-containing
regimens among ART-experienced participants in the HIV Outpatient Study.
Buchacz K, Wiegand R, Armon C,
et al
HIV Clin Trials. 2015 Jul
1:
Abstract -
Early antiretroviral therapy with raltegravir generates sustained reductions in
HIV reservoirs but not lower T-cell activation levels.
Hey-Cunningham WJ, Murray JM, et al
AIDS. 2015 Feb 27
Abstract -
Efficacy and Tolerability of 3 Nonnucleoside Reverse
Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive
Volunteers Infected With HIV-1: A Randomized, Controlled Equivalence Trial.
Lennox JL, Landovitz RJ, Ribaudo HJ, et al
Ann
Intern Med. 2014 Oct 7;161(7):461-71.
Abstract
Efficacy and safety of switching to raltegravir
plus atazanavir dual therapy in pretreated
HIV-1-infected patients over 144 weeks: a cohort
study.
Gantner P, Koeppel C, Partisani M, et al
Scand
J Infect Dis.
2014 Sep 17:1-8
Abstract -
FULL-TEXT ARTICLE
The RADAR Study: Week 48 Safety and Efficacy of RAltegravir
Combined with Boosted DARunavir Compared to
Tenofovir/Emtricitabine Combined with Boosted Darunavir in
Antiretroviral-Naive Patients. Impact on Bone Health.
Bedimo RJ, Drechsler H, Jain M, et al
PLoS One.
2014 Aug 29;9(8):e106221.
Paper -
Rate and determinants of residual viremia in
multidrug-experienced patients successfully treated with raltegravir-based
regimens.
Baroncelli S, Pirillo MF, Galluzzo CM, et al
AIDS Res Hum Retroviruses.
2014 Aug 5
Abstract -
Impact of prior virologic failure and nucleos(t)ide
genotypic resistance mutations on the efficacy of switching from
ritonavir-boosted protease inhibitors to raltegravir.
Blanco JL, Gonzalez-Cordón A, Llibre JM, .et al
Antivir Ther. 2014
Jun 25.
Abstract -
Long-term efficacy and safety of raltegravir in the
management of HIV infection.
Liedtke MD, Tomlin CR, Lockhart SM, et al
Infect Drug Resist. 2014 Mar
18;7:73-84.
Abstract -
Raltegravir as antiretroviral therapy in HIV/AIDS.
Sharma M, Walmsley SL.
Expert Opin Pharmacother.
2014 Feb;15(3):395-405.
Abstract -
Raltegravir-emtricitabine-tenofovir as HIV
nonoccupational post-exposure prophylaxis in men who have sex with
men: safety, tolerability and adherence.
McAllister J, Read P, McNulty A, et al
HIV Med. 2013 Sep
6
Abstract -
Combination antiretroviral therapy with Raltegravir leads to rapid
immunologic reconstitution in treatment-naive patients with chronic
HIV infection.
Pallikkuth S, Fischl MA, Pahwa S.
J Infect Dis. 2013 Aug 6.
Abstract -
Clinical Experience of Raltegravir with
Abacavir/Lamivudine or Zidovudine/Lamivudine in HIV-Infected Korean
Adults.
Kang SJ, An JH, Kim J, et al
Jpn J Infect Dis.
2013;66(4):317-9.
Abstract -
Pharmacokinetic Study of Dual Therapy With Raltegravir
400 mg Twice Daily and Darunavir/Ritonavir 800/100 mg Once Daily in
HIV-1-Infected Patients.
Martínez-Rebollar M, Muñoz A, Pérez I, et al
Ther Drug Monit. 2013 Aug;35(4):552-6.
Abstract -
FULL-TEXT ARTICLE
Raltegravir for HIV-1 infected children and adolescents:
efficacy, safety, and pharmacokinetics.
Larson KB, King JR, Acosta EP.
Adolesc Health Med Ther.
2013 Aug 27;4:79-87
Paper -
Effects of Raltegravir on 2-LTR circles junctions in
HIV-1 viremic and aviremic patients.
Bona R, Baroncelli S, d'Ettorre G, et al
AIDS Res Hum Retroviruses.
2013 Jun 26
Abstract -
Efficacy and safety of raltegravir for treatment of HIV
for 5 years in the BENCHMRK studies: final results of two randomised,
placebo-controlled trials.
Eron JJ, Cooper DA, Steigbigel RT, et al
Lancet Infect Dis.
2013 May 7
Abstract -
A cohort study of treatment-experienced
HIV-1-infected patients treated with raltegravir: factors
associated with virological response and mutations selected
at failure.
Marcelin AG, Delaugerre C, Beaudoux C, et al
Int J Antimicrob Agents.
2013 Apr 4
Abstract -
Durable Efficacy and Safety of Raltegravir
versus Efavirenz When Combined With Tenofovir/Emtricitabine
In Treatment-Naive HIV-1 Infected Patients: Final Five-Year
Results From STARTMRK.
Rockstroh JK, Dejesus E, Lennox JL, et al
J Acquir Immune Defic Syndr.
2013 Feb 13
Abstract -
Safety, Tolerability, and Efficacy of
Raltegravir in a Diverse Cohort of HIV-Infected Patients:
48-week Results from the REALMRK Study.
Squires K, Bekker LG, Eron JJ, et al
AIDS Res Hum Retroviruses.
2013 Jan 25.
Abstract -
Safety and efficacy of a raltegravir-based
dual antiretroviral therapy in clinical practice.
Cenderello G, Penco G, Pontali E, et al
J Int AIDS Soc.
2012 Nov 11;15(6):18353.
Abstract -
Observational study on HIV-1-infected patients treated with
an ARV combination therapy including raltegravir:
the RACING cohort results at month 12.
Pugliese P, Poizot-Martin I, Billaud E, et al
J Int AIDS Soc. 2012 Nov
11;15(6):18398.
Abstract -
A randomized pilot study of tenofovir/emtricitabine
(TDF/FTC) + boosted atazanavir (ATV/r) vs. raltegravir (RAL
BID) + ATV/r
vs. RAL BID + ATV BID.
Cohen C, Green J, Olivet H,
et alJ
Int AIDS Soc. 2012 Nov 11;15(6):18279.
Abstract -
Raltegravir 800 mg once-daily is efficacious
in already virologically suppressed patients.
Ward D, Grant R.
J
Int AIDS Soc. 2012 Nov
11;15(6):18380.
Abstract -
Safety and efficacy of raltegravir in patients co-infected with
HIV and hepatitis B and/or C virus:
complete data from Phase III double-blind
studies.
Rockstroh J, Sklar P, Wan H,
J
Int AIDS Soc. 2012 Nov 11;15(6):18415.
Abstract -
Dual raltegravir/etravirine combination in
virologically suppressed HIV-1-infected patients on
antiretroviral therapy.
Calin R, Paris L, Simon A,
et al
Antivir Ther. 2012
Sep 3.
Abstract -
The role of raltegravir in the treatment of
HIV-2 infections: evidence from a case series.
Peterson K, Ruelle J, Vekemans M,
et al
Antivir Ther. 2012
Aug 15
Abstract
'
-
Efficacy of raltegravir versus efavirenz when
combined with tenofovir/emtricitabine in treatment-naïve
HIV-1-infected patients: week-192 overall and subgroup
analyses from STARTMRK.
DeJesus E, Rockstroh JK, Lennox JL,
et al
HIV Clin Trials .
2012 Jul-Aug
Abstract
'
-
FULL-TEXT
ARTICLE
96 Week Follow-Up of HIV-Infected Patients in Rescue with
Raltegravir Plus Optimized Backbone Regimens: A Multicentre
Italian Experience.
Capetti A, Landonio S, Meraviglia P, et al
PLoS One.
2012;7(7):e39222
Paper
-
Sustained Efficacy and Safety of Raltegravir
after 5 Years of Combination Antiretroviral Therapy as
Initial Treatment of HIV-1 Infection: Final Results of a
Randomized, Controlled, Phase II Study (Protocol 004).
Gotuzzo E, Markowitz M, Ratanasuwan W,, et al
J Acquir Immune Defic Syndr.
2012 Jun 27.
Abstract
-
A randomized study of pharmacokinetics, efficacy and safety
of two raltegravir plus atazanavir strategies
in ART-treated adults.
Carey D, Pett SL, Bloch M,
et al
J Acquir Immune Defic Syndr.
2012 Mar 14.
Abstract
-
Impaired maraviroc and raltegravir clearance in a human
immunodeficiency virus-infected patient with end-stage
liver
disease and renal impairment: a management dilemma.
Pau AK, Penzak SR, Boyd SD, et
al
Pharmacotherapy.
2012 Jan;32(1):
Abstract
-
Potent and Sustained Antiviral Response of Raltegravir-based Highly
Active Antiretroviral Therapy in
HIV Type 1-infected Children and Adolescents.
Briz V, León-Leal JA, Palladino C,
et
al
Pediatr Infect Dis J.
2012 Mar;31(3):273-277.
Abstract
-
Long-term Efficacy and Safety of Raltegravir, Etravirine, and
Darunavir/Ritonavir in
Treatment-Experienced Patients: Week 96 Results from the ANRS 139 TRIO
Trial.
Fagard C, Colin C, Charpentier C, et al
J Acquir Immune Defic Syndr.
2012 Jan 30
Abstract
-
Raltegravir, Tenofovir DF, and Emtricitabine for
Post-Exposure Prophylaxis to Prevent
the Sexual Transmission ofO
HIV: Safety, Tolerability, and Adherence.
Mayer KH, Mimiaga MJ, Gelman M, Grasso C.
J Acquir Immune Defic Syndr.
2012 Jan 19
Abstract
-
Raltegravir in HIV-1 infection: Safety and Efficacy in
Treatment-naïve Patients.
Pandey KK.
Clin Med Rev Ther.
2011 Dec 20;2012(4):13-30.
Abstract
-
Immunologic Effectiveness of Maraviroc- and Raltegravir-Containing
Regimens (R+M+) versus
Raltegravir-Based Regimens That Do Not Include Maraviroc (R+M-).
Antoniou T, Smith G, Su D, et al
J Int Assoc Physicians AIDS Care (Chic
Abstract
-
Successful tacrolimus treatment following renal
transplant in a HIV-infected patient with raltegravir previously
treated with a protease inhibitor based regimen.
Cousins D, Topping K, Lee V, et al
Drug Metabol Drug Interact.
2011;26(3):139-41.
Abstract
-
Raltegravir in a special case - Patient with HIV and
Burkitt's lymphoma
Bieniek B.
Dtsch Med Wochenschr.
2011 Oct;136(41):2091-3.
Abstract
-
Long-term Treatment With Raltegravir or Efavirenz Combined With
Tenofovir/Emtricitabine
for Treatment-Naive Human Immunodeficiency Virus-1-Infected Patients:
156-Week Results From STARTMRK.
Rockstroh JK, Lennox JL,
Dejesus E,
et
al
Clin Infect Dis. 2011
Oct;53(8):807-816.
Abstract
-
Role of raltegravir in the management of HIV-1
infection.
Okeke NL, Hicks C.
HIV AIDS (Auckl). 2011;3:81-92.
Abstract
-
Similar efficacy of raltegravir when used with or without a protease
inhibitor in treatment-experienced patients.
Skiest DJ, Cohen C, Mounzer K, et al
HIV Clin Trials.
2011 May-Jun;12(3):131-40.
Abstract
-
Efficacy and safety of raltegravir in
treatment-experienced HIV-1-infected patients switching from
enfuvirtide-based
regimens: 48 week results of the randomized EASIER
ANRS 138 trial.
Gallien S, Braun J, Delaugerre C, Charreau I, et al
J Antimicrob Chemother. 2011
Jun 28.
Abstract
-
Similar efficacy of raltegravir when used with or without a protease
inhibitor in treatment-experienced
patients.
Skiest DJ, Cohen C, Mounzer K,
et al
HIV Clin Trials. 2011
May-Jun;12(3):131-40.
Abstract
-
Safety and efficacy of raltegravir in patients with HIV-1 and
hepatitis B and/or C
virus coinfection.
Rockstroh J, Teppler H, Zhao J, et al
HIV Med. 2011
May 22.
Abstract
-
Clinical Efficacy of Raltegravir Against B and Non-B
Subtype HIV-1 in the STARTMRK and BENCHMRK Studies.
Rockstroh JK, Teppler H, Zhao J, et al
AIDS. 2010 Apr 25
Abstract
-
Use of Maraviroc-, Raltegravir-, and Etravirine-Containing Regimens in
Treatment-Experienced Patients:
A Case-Series Study.
Youngblood C, Sayana S, Khanlou H.
J Int Assoc Physicians AIDS Care (Chic).
2011 Mar 23
Abstract
-
Raltegravir and unboosted atazanavir dual therapy in
virologically suppressed antiretroviral
treatment-experienced HIV patients.
Cordery DV, Hesse K, Amin
J, Cooper DA.
Antivir
Ther. 2010;15(7):1035-8
Abstract
-
FULL-TEXT ARTICLE
Optimal
use of raltegravir (Isentress(R)) in the treatment of HIV-infected
adults -
Canadian consensus guidelines.
Rachlis A, Angel JB, Harris M, et al
Can J Infect Dis Med Microbiol.
2009 Fall;20(3):e67-80.
Paper -
Long-term successful control of super-multidrug-resistant human
immunodeficiency
virus type 1 infection by a novel combination therapy of raltegravir,
etravirine, and
boosted-darunavir.
Nakamura H, Miyazaki N, Hosoya N, et al
J Infect Chemother. 2010 Jun
30
Abstract
-
Raltegravir Versus Efavirenz Regimens in Treatment-Naive
HIV-1-Infected Patients:
96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic
Analyses.
Lennox JL, Dejesus E, Berger DS, et al
J Acquir Immune Defic Syndr.
2010 Apr 15
Abstract
-
Raltegravir Plasma Concentrations in Treatment-Experienced Patients
Receiving Salvage
Regimens Based on Raltegravir With and Without Maraviroc
Coadministration (May).
Baroncelli S, Villani PA, Weimer LE,
et al
Ann Pharmacother. 2010 Apr 6
Abstract
-
Raltegravir: In Treatment-Naive Patients with HIV-1
Infection.
Croxtall JD, Scott LJ.
Drugs.
2010 Mar 26;70(5):631-42.
Abstract
-
Long-Term Efficacy and Safety of Raltegravir Combined with Optimized
Background
Therapy in Treatment-Experienced Patients with Drug-Resistant HIV
Infection:
Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials.
Steigbigel RT, Cooper DA, Teppler H, et al
Clin Infect Dis.
2010 Jan 19
Abstract
|
|
|
-
High-performance liquid chromatography-tandem mass spectrometry for
simultaneous determination of raltegravir, dolutegravir, and elvitegravir
concentrations in human plasma and cerebrospinal fluid samples.
Tsuchiya K, Ohuchi M, Yamane N,
et al
Biomed Chromatogr. 2017
Jul 31
Abstract
-
FULL-TEXT PDF ARTiCLE
A rapid
validated UV-HPLC method for the simultaneous determination of the
antiretroviral compounds darunavir and raltegravir in their dosage form.
Estan-Cerezo G, García-Monsalve A, Soriano-Irigaray L, et a
Rev Esp Quimioter. 2017 Mar
29.
Paper
-
FULL-TEXT ARTICLE
Electrocardiographic findings in a cross-sectional study of human
immunodeficiency virus (HIV) patients in Enugu, south-east Nigeria
Njoku PO, Ejim EC, Anisiuba BC, Ike SO, Onwubere BJ.
Cardiovasc J Afr.
2016 Jul/Aug;27(4):252-257.
Paper
Development and validation of a liquid chromatographic-tandem
mass spectrometric method for the multiplexed quantification of etravirine,
maraviroc, raltegravir, and rilpivirine in human plasma and tissue.
Parsons TL, Marzinke MA.
J Pharm Biomed Anal. 2016 Sep 4;131:333-344.
Abstract
-
A micellar liquid chromatography method for the quantification of abacavir,
lamivudine and raltegravir in plasma.
Peris-Vicente J, Villareal-Traver M, Casas-Breva I,
et al
J Pharm Biomed Anal. 2014
Jun 13;98C:351-355.
Abstract
-
Poor performance of laboratories assaying newly developed
antiretroviral agents: results for darunavir, etravirine and raltegravir
from The International Quality Control Program for Therapeutic Drug
Monitoring of Antiretroviral Drugs in Human Plasma/Serum.
Burger D, Krens S, Robijns K,
et al
Ther Drug Monit. 2014 May 9
Abstract
-
FULL-TEXT ARTICLE
Comparison of illumina and 454 deep sequencing in participants failing
raltegravir-based antiretroviral therapy.
Li JZ, Chapman B, Charlebois P, et al
PLoS One. 2014 Mar
6;9(3):e90485.
-
Minimal Sequence Variability of the Region of HIV-1 Integrase
Targeted by the Abbott RealTime HIV-1 Viral Load Assay in Clinical Specimens
with Reduced Susceptibility to Raltegravir.
Young TP, Napolitano LA, Paquet AC, et al
J Virol Methods. 2013
Jul 25
Abstract
-
Simultaneous quantitation of azole antifungals, antibiotics,
imatinib, and raltegravir in human plasma by two-dimensional high-performance
liquid chromatography-tandem mass spectrometry.
Jourdil JF, Tonini J, Stanke-Labesque F.
J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Jan
9;919-920C:1-9.
Abstract
-
Validation of an UPLC-MS/MS Method for Quantitative Analysis of
Raltegravir in Human Plasma Samples.
Fortuna S, Ragazzoni E, Lisi L,
et al
Ther Drug Monit. 2013 Feb 12.
Abstract
-
A pilot study to assess inflammatory biomarker changes when raltegravir is
added to
a virologically suppressive haart regimen in HIV-1-infected patients with
limited immunologic responses.
Lichtenstein KA, Armon C, Nagabhushanam V,
et al
Antivir Ther. 2012 Sep 5.
Abstract
-
Measurement of plasma and intracellular concentrations of
raltegravir in patients with HIV infection.
Sandkovsky US, Swindells S, Robbins BL,
et al
AIDS. 2012 Aug 31.
Abstract
-
A novel ultrasensitive LC-MS/MS assay for quantification of
intracellular raltegravir in human cell extracts.
Robbins BL, Nelson SR, Fletcher CV.
J Pharm Biomed Anal. 2012 Jun 2. [
Abstract
-
A sensitive liquid chromatography coupled with mass spectrometry method for the
intracellular and plasma
quantification of raltegravir after solid-phase extraction.
Mosnier-Thoumas S, Djabarouti S, Xuereb F, et al
J Pharm Pharmacol. 2011
Dec;63(12):1559-65.
Abstract
-
Clinical evaluation of the determination of plasma
concentrations of darunavir, etravirine,
raltegravir and ritonavir in dried blood spot samples.
Ter Heine R, Mulder JW, van Gorp EC, et
al
Bioanalysis. 2011
May;3(10):1093-7
Abstract
-
Limited Sampling Strategies for the Estimation of Raltegravir
Daily Exposure in HIV-Infected Patients.
Cattaneo D, Ripamonti D, Gervasoni C,
et al
J Clin Pharmacol. 2011 Mar 7.
Abstract
-
Simultaneous determination of raltegravir and
raltegravir glucuronide in human plasma by liquid
chromatography-tandem mass spectrometric method.
Wang LZ, Lee LS, Thuya WL, et al
J Mass Spectrom. 2011 Jan
24:202-208.
Abstract
|
-
Incidence and risk factors for liver enzymes elevations in highly
treatment-experienced patients switching from enfuvirtide to
raltegravir: a sub-study of the ANRS-138 EASIER trial.
de Castro N, Braun J, Charreau I, et al
AIDS Res Ther. 2016 Apr 2;13:17.
Abstract
-
Antiretroviral resistance at virological failure in the NEAT 001/ANRS
143 trial: raltegravir plus darunavir/ritonavir or
tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Lambert-Niclot S, George EC, Pozniak A, et al
J Antimicrob Chemother.
2016 Apr;71(4):1056-62.
Abstract
-
The dolutegravir R263K resistance mutation in HIV-1 integrase is
incompatible with the emergence of resistance against raltegravir.
Oliveira M, Mesplède T, Moïsi
D, et al
AIDS. 2015 Sep 13.
Abstract
-
FULL-TEXT ARTICLE
Integrase inhibitor (INI) genotypic resistance in treatment-naive and
raltegravir-experienced patients infected with diverse HIV-1 clades.
Doyle T, Dunn DT, Ceccherini-Silberstein F, et al
J Antimicrob Chemother.
2015 Aug 26. pii: dkv243.
Paper
-
Combination of two pathways involved in raltegravir resistance confers
dolutegravir resistance.
Malet I, Thierry E, Wirden M,
J Antimicrob Chemother.
2015 Jul 23.
Abstract
-
Cross-resistance to elvitegravir and dolutegravir in 502 patients
failing on raltegravir: a French national study of
raltegravir-experienced HIV-1-infected patients.
Fourati S, Charpentier C, Amiel C,
et
al
J Antimicrob Chemother.
2015 Jan 3.
Abstract
-
Impact of the HIV integrase genetic context on the phenotypic expression
and in vivo emergence of raltegravir resistance mutations.
Nguyen TT, Rato S, Molina JM, et al
J Antimicrob Chemother.
2014 Oct 21.
Abstract
-
4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing
Compounds Having High Potency against Raltegravir-Resistant Integrase
Mutants of HIV-1.
Zhao XZ, Smith SJ, Métifiot M, et al
J Med Chem. 2014 Jun 16.
Abstract
-
New raltegravir resistance pathways induce broad
cross-resistance to all currently used integrase inhibitors.
Malet I, Gimferrer Arriaga L, Artese A, et al
J Antimicrob Chemother. 2014 Apr
7.
Abstract
-
Raltegravir and elvitegravir-resistance mutation E92Q affects HLA-B*40:02-restricted
HIV-1-specific CTL recognition.
Rahman MA, Kuse N, Murakoshi H, et al
Microbes Infect. 2014
Mar 20.
Abstract
-
Bicyclic
1-Hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-Containing HIV-1
Integrase Inhibitors Having High Antiviral Potency against Cells
Harboring Raltegravir-Resistant Integrase Mutants.
Zhao XZ, Smith SJ, Métifiot M, et al
J Med Chem. 2014 Feb
27;57(4):1573-82
Abstract
-
Multiple Genetic Pathways Involving Amino Acid Position 143
of HIV-1 Integrase Are Preferentially Associated with Specific Secondary
Amino Acid Substitutions and Confer Resistance to Raltegravir and
Cross-Resistance to Elvitegravir.
Huang W, Frantzell A, Fransen S, Petropoulos CJ.
Antimicrob Agents Chemother. 2013
Jun 3
Abstract
-
Raltegravir resistance in the cerebrospinal fluid.
Mora-Peris B, Mackie NE, et al
Infection. 2013 Feb 3.
Abstract
-
FULL-TEXT ARTICLE
Prolonged and Substantial Discordance in Prevalence of
Raltegravir-Resistant HIV-1 in Plasma versus PBMC Samples Revealed by
454 "Deep" Sequencing.
Lee GQ, Swenson LC, Poon AF, et al
PLoS One.
2012;7(9):e46181.
Paper
-
Understanding the
effect of drug-resistant mutations of HIV-1 intasome on raltegravir action
through molecular modeling study.
Xue W, Qi J, Yang Y, et al
Mol Biosyst. 2012 May 30.
Abstract
-
Prevalence of HIV-1 integrase mutations related to
resistance to dolutegravir in raltegravir naïve and pretreated patients.
Saladini F, Meini G, Bianco C,
et al
Clin Microbiol Infect.
2012 May 28.
Abstract
-
In-vivo Selection of the Mutation F121Y in a Patient
Failing Raltegravir Containing Salvage Regimen.
Cavalcanti JD, Lança AM, Ferreira JL,
et al
Antiviral Res. 2012 May 4.
Abstract
-
Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected
Patients Failing on
Raltegravir-Containing Regimens.
Garrido C, Villacian J, Zahonero N, et al
Antimicrob Agents Chemother.
2012 Mar 26
Abstract
-
Analyses of transmitted resistance and selective pressure
in HIV-1 naive patients to Raltegravir and failure HAART in Sao Paulo,
Brazil.
Mantovani NP, Azevedo RG, Rabelato JT, et al
J Clin Microbiol. 2012 Mar 7
Abstract
-
Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations
During Raltegravir Treatment:
A Refined Analysis by Ultra-Deep 454 Pyrosequencing.
Armenia D, Vandenbroucke I, Fabeni L, et al
J Infect Dis. 2012 Jan 11.
Abstract
-
In vitro resistance selections using elvitegravir, raltegravir, and
two metabolites of elvitegravir
M1 and M4.
Margot NA, Hluhanich RM, Jones GS, et al
Antiviral Res. 2011
Dec 16.
Abstract
-
Long-lasting persistence of integrase resistance mutations in
HIV-2-infected patients
after raltegravir withdrawal.
Charpentier C, Larrouy L, Matheron S,
et al
Antivir Ther. 2011;16(6):937-940.
Abstract
-
MK-0536 inhibits HIV-1 integrases resistant to
raltegravir.
Métifiot M, Johnson B, Smith S,
et
al
Antimicrob Agents Chemother.
2011 Aug 29.
Abstract
-
Switching between raltegravir resistance pathways analyzed
by deep sequencing.
Mukherjee R, Jensen ST, Male F,
et al
AIDS. 2011 Aug 9.
Abstract
-
Resistance to raltegravir highlights integrase mutations at
codon 148 in conferring
cross-resistance to a second-generation HIV-1 integrase inhibitor.
Goethals O, Van Ginderen M, Vos A, et al
Antiviral Res. 2011
Jun 12;91(2):167-176.
Abstract
-
Single Mutations in HIV Integrase Confer High-Level
Resistance to Raltegravir in Primary Human Macrophages.
Marsden MD, Avancena P, Kitchen CM,
et
al
Antimicrob Agents Chemother. 2011
May 31.
Abstract
-
Elvitegravir overcomes resistance to raltegravir induced by
integrase mutation Y143.
Métifiot M, Vandegraaff N, Maddali K, et al
AIDS. 2011 Apr 18.
Abstract
-
The SnoB study: frequency of baseline raltegravir
resistance mutations prevalence in different non-B subtypes.
Sierra S, Lübke N, Walter H, et al
Med Microbiol Immunol. 2011 Apr 8
Abstract
-
Transmission of integrase strand-transfer inhibitor
multidrug-resistant HIV-1: case report and response to
raltegravir-containing antiretroviral therapy.
Young B, Fransen S, Greenberg KS, Thomas A, et al
Antivir Ther. 2011;16(2):253-6.
Abstract
-
Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected
patient.
Boyd SD, Maldarelli F, Sereti I,
et al
Antivir Ther.
2011;16(2):257-61.
Abstract
-
Plasma raltegravir exposure influences the antiviral
activity and selection of resistance mutations.
Garrido C, de Mendoza C, Alvarez E, et al
AIDS Res Hum Retroviruses. 2011
Apr 3
Abstract
-
Prevalence of resistance mutations related to integrase
inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated
patients.
Malet I, Wirden M, Fourati S,
et al
J Antimicrob Chemother.
2011 Apr 7
Abstract
-
Emerging integrase inhibitor resistance mutations in raltegravir-treated
HIV-1-infected patients
with low-level viremia.
Gallien S, Delaugerre C, Charreau I, et al.
AIDS. 2011 Feb 14
Abstract
-
Emergence of raltegravir-resistant HIV-1 in the central
nervous system.
Watanabe K, Honda M, Watanabe T, et al
Int J STD AIDS.
2010 Dec;21(12):840-1.
Abstract
-
Hot spots of integrase genotypic changes leading to HIV-2
resistance to raltegravir.
Charpentier C, Roquebert B, Delelis O, et al
Antimicrob Agents Chemother.
2010 Dec 28.
Abstract
-
Analysis of low frequency mutations associated with drug-resistance to
raltegravir before
antiretroviral treatment.
Liu J, Miller MD, Danovich RM,
et al
Antimicrob Agents Chemother.
2010 Dec 20
Abstract
-
Genetic barrier to antiretroviral drug-resistance. Focus on
raltegravir, the first integrase inhibitor
Delaugerre C.
Med Mal Infect. 2010 Sep;40 Suppl
1:S1-10.
Abstract
Resistance analyses in highly experienced patients failing
raltegravir, etravirine and darunavir/ritonavir regimen.
Charpentier C, Roquebert B, Colin C, et al
AIDS. 2010 Aug 26
Abstract
-
Discovery of potent HIV integrase inhibitors active against
raltegravir resistant viruses.
Le G, Vandegraaff N, Rhodes DI, et al
Bioorg Med Chem Lett. 2010 Jul 16.
Abstract
-
Effect of Raltegravir Resistance Mutations in HIV-1
Integrase on Viral Fitness.
Hu Z, Kuritzkes DR.
J Acquir Immune Defic Syndr.
2010 Jul 14
Abstract
-
FULL-TEXT ARTICLE
The HIV-1 integrase mutations Y143C/R are an alternative pathway for
resistance
to Raltegravir and impact the enzyme functions.
Reigadas S, Anies G, Masquelier B, et al
PLoS One.
2010 Apr 26;5(4):e10311.
Paper
-
Primary mutations selected in vitro with raltegravir confer large fold
changes
in susceptibility to first-generation integrase inhibitors, but minor fold
changes
to inhibitors with second-generation resistance profiles.
Goethals O, Vos A, Van Ginderen M, . et al
Virology.
2010 Apr 24.
Abstract
-
HIV-1 resistance patterns to integrase inhibitors in
antiretroviral-experienced patients with
virological failure on raltegravir-containing regimens.
da Silva D, Van Wesenbeeck L, Breilh D,
et al
J Antimicrob Chemother.
2010 Apr 12
Abstract
-
Biochemical and Pharmacological Analyses of HIV-1 Integrase
Flexible Loop Mutants
Resistant To Raltegravir.
Métifiot M, Maddali K, Naumova A, Zhang X, et al.
Biochemistry. 2010 Mar 24.
Abstract
-
Raltegravir as functional monotherapy leads to virological failure and
drug
resistance in highly treatment-experienced HIV-infected patients.
Caby F, Valin N, Marcelin AG, Schneider L, et al
Scand J Infect Dis.
2010 Mar 12.
Abstract
-
The HIV-1 integrase genotype strongly predicts
raltegravir susceptibility but
not viral fitness of primary virus
isolates.
Buzón MJ, Dalmau J, Puertas MC, et al
AIDS.
2010 Jan 2;24(1):17-25.
Abstract
|
-
Incidence of cancer and overall risk of mortality in individuals treated with
raltegravir-based and non-raltegravir-based combination antiretroviral therapy
regimens.
Cozzi-Lepri A, Zangerle R, Machala L, et al
HIV Med.
2017 Oct 6.
Abstract
-
FULL-TEXT ARTICLE
Facial botryomycosis-like pyoderma in an HIV-infected patient: remission after
initiation of darunavir and raltegravir.
Eyer-Silva WA, Silva GARD, Ferry FRA,
Lancet HIV.
2017 May 26.
Paper
-
Association of the HLA-B*53:01 Allele With Drug Reaction
With Eosinophilia and Systemic Symptoms (DRESS) Syndrome
During Treatment of HIV Infection With Raltegravir.
Thomas M, Hopkins C, Duffy E, et al
Clin Infect Dis.
2017 Mar 21
Abstract
-
Incidence and risk factors for liver enzymes elevations in
highly treatment-experienced patients switching from
enfuvirtide to raltegravir: a sub-study of the ANRS-138
EASIER trial.
de Castro N, Braun J, Charreau I, et al
AIDS Res Ther. 2016 Apr 2;13:17.
Abstract
-
A Reduction Grade of Lipodystrophy and
Limited Side Effects after HAART Regimen with Raltegravir,
Lamivudine, Darunavir and Ritonavir in an HIV-1
Infected Patient after Six Years of Antiretroviral Therapy.
Degli Antoni A, Weimer LE, Fragola V,
et al
West Indian Med J.
2015 Jul 14;64(3).
Abstract
-
Allergic hypersensitivity to antiretroviral
drugs: etravirine, raltegravir and darunavir.
Sánchez-Olivas MA, Valencia-Zavala MP, Vega-Robledo GB,
et al
Rev Alerg Mex. 2015
Apr-Jun;62(2):142-148
Abstract
-
Skeletal Muscle Toxicity in HIV-1-Infected Patients Treated
with a Raltegravir-Containing Antiretroviral Therapy: A
Cohort Study.
Calza L, Danese I, Colangeli V, et al
AIDS Res Hum Retroviruses.
2014 Nov 4.
Abstract
-
Reduced platelet hyperreactivity and
platelet-monocyte aggregation in HIV-infected individuals
receiving a raltegravir-based regimen.
Tunjungputri RN, Van Der Ven AJ, Schonsberg A, et al
AIDS. 2014 Sep
10;28(14):2091-209
Abstract
-
Bone mineral density over 96 weeks in adults
failing first-line therapy randomised to
raltegravir/lopinavir/ritonavir compared to standard
second-line therapy.
Haskelberg H, Mallon PW, Hoy J, et al
J Acquir Immune Defic Syndr.
2014 Jul 25.
Abstract
-
Extensive pulmonary involvement with
raltegravir-induced DRESS syndrome in a postpartum woman
with HIV.
Yee BE, Nguyen NH, Lee D.
BMJ Case Rep. 2014
May 5;2014.
Abstract
-
Persistent prurigo nodularis in HIV-infected
patient responsive to antiretroviral therapy with
raltegravir.
Motegi SI, Kato M, Uchiyama A, et al
J Dermatol.
2014 Jan 31
Abstract
-
Transient increment of HTLV-2 proviral load
in HIV-1-co-infected patients during treatment
intensification with raltegravir.
Abad-Fernández M, Cabrera C, García E, Vallejo A.
J Clin Virol. 2014 Jan 7.
Abstract
-
FULL-TEXT
ARTICLE
Dynamics of Immune Reconstitution and Activation Markers in
HIV+ Treatment-Naïve Patients Treated with Raltegravir,
Tenofovir Disoproxil Fumarate and Emtricitabine.
Funderburg NT, Andrade A, Chan ES, et al
PLoS One. 2013 Dec
18;8(12):e83514.
Paper
-
Treatment with suboptimal doses of
raltegravir leads to aberrant HIV-1 integrations.
Varadarajan J, McWilliams MJ, Hughes SH.
Proc Natl Acad Sci U S A.
2013 Aug 19
Abstract
-
FULL-TEXT
ARTICLE
Switching Tenofovir/Emtricitabine plus Lopinavir/r to
Raltegravir plus Darunavir/r in Patients with Suppressed
Viral Load Did Not Result in Improvement of Renal Function
but Could Sustain Viral Suppression: A Randomized
Multicenter Trial.
Nishijima T, Gatanaga H, Shimbo T, et al
PLoS One.
2013 Aug 8;8(8):e73639.
Paper
-
Rapid onset of rhabdomyolysis after switching
to a raltegravir-based antiretroviral regimen.
Tsai WJ, Lee SS, Tsai HC, et al
J Microbiol Immunol Infect.
2013 Apr 20.
Abstract
-
Skeletal muscle toxicity associated with
raltegravir-based combination anti-retroviral therapy in
HIV-infected adults.
Lee FJ, Amin J, Bloch M, et al
J Acquir Immune Defic Syndr.
2012 Dec 28.
Abstract
-
Resolution of autoimmune thrombocytopenia
associated with raltegravir use in an HIV-positive patient.
Gentile I, Bonadies G, Buonomo AR,
et al
Platelets. 2012 Nov 6.
Abstract
-
Raltegravir central nervous system
tolerability in clinical practice: results from a
multicenter observational study.
Madeddu G, Menzaghi B, Ricci E,
et
al
AIDS. 2012 Oct 1.
Abstract
-
Raltegravir-induced DRESS syndrome.
Loulergue P, Mir O.
Scand J Infect Dis.
2012 Jul 17
Abstract
-
Severe dyslipidaemia after the addition of
raltegravir to a lopinavir/ritonavir-containing regimen.
Huesgen E, Burgos R, Goldstein DA, et al
Antivir Ther. 2012
Jun 22.
Abstract
-
Body Composition Changes after Switching from Protease
Inhibitors to Raltegravir: SPIRAL-LIP substudy.
Curran A, Martinez E, Saumoy M, et al
AIDS. 2011 Nov
22.
Abstract
-
Development of Buffalo Hump in the course of antiretroviral therapy
including raltegravir and unboosted
atazanavir: a case report and review of the literature.
Ceccarelli G, d'Ettorre G,
Marchetti F, et al
J Med Case Reports. 2011 Feb 17;5(1):70
Abstract
-
Severe raltegravir-associated rhabdomyolysis: a case
report and review of the literature.
Croce F, Vitello P, Dalla Pria A, et al
Int J STD AIDS. 2010
Nov;21(11):783-5.
Abstract
|
-
An observational, retrospective analysis evaluating switching to
raltegravir plus abacavir/lamivudine in HIV-1-infected patients:
the ORASWIRAL study.
Galli L, Poli A, Muccini C, et al
Infect Dis (Lond).
2017 Sep 11:1-3.
Abstract
-
Total cellular HIV-1 DNA decreases after switching to
raltegravir-based regimens in patients with suppressed HIV-1
RNA.
Rossetti B, Meini G, Bianco C, et al
J Clin Virol.
2017 Mar 23;91:18-24.
Abstract
-
Switching to Raltegravir From a Virologically
Effective Boosted Protease Inhibitor Regimen: A Comparative
Effectiveness Analysis From the French Hospital Database on HIV
(FHDH-ANRS CO4).
Potard V, Simon A, Lacombe JM,
et al
Clin Infect Dis.
2016 Aug 19.
Abstract
-
Raltegravir in second-line antiretroviral therapy in
resource-limited settings (SELECT): a randomised, phase 3,
non-inferiority study.
La Rosa AM, Harrison LJ, Taiwo B,
et al
Lancet HIV.
2016 Jun;3(6):e247-58.
Abstract
-
A randomized clinical trial comparing
ritonavir-boosted lopinavir versus raltegravir each with
tenofovir plus emtricitabine for post-exposure prophylaxis for
HIV infection.
Leal L, León A, Torres B, Inciarte A,
et al
J Antimicrob Chemother.
2016 Mar 18.
Abstract
-
FULL-TEXT ARTICLE
Efficacy and safety of antiretroviral regimens including
raltegravir to treat
HIV-infected patients with hemophilia.
Xiao H, Xue Y, Gu S, et al
Biosci Trends.
2016 Mar 10;10(1):42-6.
Paper
-
Raltegravir-based HIV postexposure prophylaxis (PEP) in a
real-life clinical setting: fewer drug-drug interactions (DDIs)
with improved adherence and tolerability.
Mulka L, Annandale D, Richardson C,
et al
Sex Transm Infect.
2016 Mar;92(2):107. d
Abstract
-
Markers of HIV reservoir size and immune activation after
treatment in acute HIV infection with and without raltegravir
and maraviroc intensification.
Ananworanich J, Chomont N, Fletcher JL,
et
al
J Virus Erad.
2015;1(2):116-122.
Abstract
-
Improvement in renal function and bone mineral density after a
switch from tenofovir/emtricitabine plus ritonavir/boosted
protease inhibitor to raltegravir plus nevirapine: a pilot
study.
Calza L, Magistrelli E, Colangeli V ,
et al
Antivir Ther. 2015
Sep 25.
Abstract
-
Intensifying Antiretroviral Therapy With Raltegravir and
Maraviroc During Early Human Immunodeficiency Virus (HIV)
Infection Does Not Accelerate HIV Reservoir Reduction.
Ostrowski M, Benko E, Yue FY, Kim CJ, et al
Open Forum Infect Dis.
2015 Sep 22;2(4):ofv138.
Abstract
-
Switch to Raltegravir From Protease Inhibitor or
Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce
Visceral Fat In Human Immunodeficiency Virus-Infected Women With
Central Adiposity.
Lake JE, McComsey GA, Hulgan T, et al
Open Forum Infect Dis.
2015 Apr 26;2(2):ofv059.
Abstract
-
High frequency of dolutegravir resistance in
patients failing a raltegravir-containing salvage regimen.
de Souza Cavalcanti J, Ferreira JL, Guimarães PM, et al
J Antimicrob Chemother.
2014 Nov 10.
Abstract
-
Switch to raltegravir-based regimens and HIV DNA decrease in
patients with suppressed HIV RNA.
Bianco C, Meini G, Rossetti B, et al
J Int AIDS Soc.
2014 Nov 2;17(4(Suppl 3)):19791.
Abstract
-
Efficacy and safety of switching to raltegravir plus atazanavir
dual therapy in pretreated HIV-1-infected patients over 144
weeks: a cohort study.
Gantner P, Koeppel C, Partisani M, et al
Scand J Infect Dis.
2014 Sep 17:1-8
Abstract
-
Pharmacokinetic study of raltegravir in
HIV-infected patients with end-stage liver disease: the
LIVERAL-ANRS148 study.
Barau C, Braun J, Vincent C, et al
Clin Infect Dis. 2014
Jul 3.
Abstract
-
FULL-TEXT ARTICLE
Urinary Eicosanoid Metabolites in HIV-Infected Women with
Central Obesity Switching to Raltegravir: An Analysis from the
Women, Integrase, and Fat Accumulation Trial.
Hulgan T, Boger MS, Liao DH, et al
Mediators Inflamm.
2014;2014:803095.
Paper
-
Raltegravir for the treatment of patients
co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB):
a multicentre, phase 2, non-comparative, open-label, randomised
trial.
Grinsztejn B, De Castro N, Arnold V, et al.
Lancet
Infect Dis. 2014 Jun;14(6):459-67.
Abstract
-
A Switch to Raltegravir Improves Antiretroviral
Associated Hepatotoxicity in Individuals Coinfected with HIV and
Hepatitis C.
Cevik M, Katsarolis I, J Singh G, Nelson M.
J Infect. 2014 May 1.
Abstract
-
Four-year outcome of a PI and NRTI-sparing
salvage regimen: maraviroc, raltegravir, etravirine.
Nozza S, Galli L, Bigoloni A, Gianotti N,
et al
New Microbiol.
2014 Apr;37(2):145-51
-
Raltegravir for the treatment of patients
co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB):
a multicentre, phase 2, non-comparative, open-label, randomised
trial.
Grinsztejn B, De Castro N, Arnold V, et al
Lancet Infect Dis.
2014 Apr 9.
Abstract
-
FULL-TEXT
ARTICLE
Effects of Switching from Stavudine to Raltegravir on
Subcutaneous Adipose Tissue in HIV-Infected Patients with
HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A Clinical
and Molecular Study.
Domingo P, Gutierrez Mdel M, Gallego-Escuredo JM, et al
|
PLoS One. 2014 Feb 26;9(2):e89088
Paper
Switch to raltegravir decreases soluble CD14 in virologically
suppressed overweight women: the Women, Integrase and Fat Accumulation
Trial.
Lake J, McComsey G, Hulgan T, et al
HIV Med. 2014 Feb 10.
Abstract
-
Short Communication: Effectiveness at 48 Weeks of Switching
from Enfuvirtide to Raltegravir in Virologically Suppressed
Multidrug-Resistant HIV Type 1-Infected Patients in a Brazilian Cohort.
Westin MR, Biscione F, Ribeiro KM, et al
AIDS Res Hum Retroviruses.
2014 Feb;30(2):113-7.
Abstract
-
Spatial modeling of HIV cryptic viremia and 2-LTR formation
during raltegravir intensification.
Fabian Cardozo E, Luo R, Piovoso MJ, Zurakowski R.
J Theor Biol. 2013 Dec 28.
Abstract
-
Four years data of raltegravir-based salvage therapy in
HIV-1-infected, treatment-experienced patients: the SALIR-E Study.
Capetti A, Meraviglia P, Landonio S, et al
Int J Antimicrob Agents.
2013 Nov 15
Abstract
-
FULL-TEXT ARTICLE
Stable HIV-1 integrase diversity during initial
HIV-1 RNA Decay suggests complete blockade of plasma HIV-1
replication by effective raltegravir-containing salvage therapy.
Noguera-Julian M, Casadellà M, Pou C, et al
Virol J. 2013 Dec 5;10(1):350.
Paper
-
Effects of switching from efavirenz to raltegravir on
endothelial function, bone mineral metabolism, inflammation, and renal
function: a randomized, controlled trial.
Gupta SK, Mi D, Moe SM,
et al
J Acquir Immune Defic Syndr.
2013 Nov 1
Abstract
-
Intensification of a raltegravir-based regimen with
maraviroc in early HIV-1 infection.
Puertas MC, Massanella M, Llibre JM,
et al
AIDS. 2013 Oct
30.
Abstract
-
Safety and efficacy of treatment switch to
raltegravir plus tenofovir/emtricitabine or
abacavir/lamivudine in patients with optimal virological
control: 48-week results from a randomized pilot study
(Raltegravir Switch for Toxicity or Adverse Events, RASTA
Study).
Fabbiani M, Mondi A, Colafigli M, et al
Scand J Infect Dis. 2013
Oct 28
Abstract
-
Increase in 2-Long Terminal Repeat Circles
and Decrease in D-dimer After Raltegravir Intensification in
Patients With Treated HIV Infection: A Randomized,
Placebo-Controlled Trial.
Hatano H, Strain MC, Scherzer R, et al
J Infect Dis.
2013 Sep 18
Abstract
-
Increase in 2-LTR Circles and Decrease in D-dimer
After Raltegravir Intensification in Treated HIV-Infected
Patients: A Randomized, Placebo-Controlled Trial.
Hatano H, Strain MC, Scherzer R, et al
J Infect Dis. 2013
Aug 23.
Abstract
-
Effectiveness at 48 weeks of switching from enfuvirtide to
raltegravir in virologically suppressed multidrug-resistant
HIV-1-infected patients in a Brazilian cohort.
Westin M, Biscione F, Ribeiro KM, et al
AIDS Res Hum Retroviruses.
2013 Jul 23
Abstract
-
Early but limited effects of raltegravir
intensification on CD4 T cell reconstitution in HIV-infected
patients with an immunodiscordant response to antiretroviral
therapy.
Negredo E, Massanella M, Puertas MC, et al
J Antimicrob Chemother.
2013 May 14.
Abstract
-
Is chewed raltegravir an option to care
HIV-infected patients with active tuberculosis?
Gervasoni C, Riva A, Impagnatiello C,
et al
Clin Infect Dis.
2013 Apr 24.
Abstract
-
Safety and efficacy of raltegravir in
patients co-infected with HIV and hepatitis B and/or C
virus: complete data from Phase III double-blind studies Rockstroh
J, Sklar P, Wan H,
J Int AIDS Soc. 2012 Nov
11;15(6):18415.
Abstract
-
Raltegravir switch improves hepatitis C
transaminitis in HIV-1 and hepatitis C (HCV) co-infected
individuals.
Cevik M, Jagjit Singh G, Dickinson L, Nelson M.
J Int AIDS Soc. 2012
Nov 11;15(6):18419
Abstract
-
Safe Coadministration of Raltegravir-Based
HAART in HIV-Infected Patients With HCV-Cirrhosis Receiving
Triple Therapy With Telaprevir or Boceprevir.
Moreno A, Quereda C, Montes M,
et
al
J Acquir Immune Defic Syndr.
2012 Nov 1;61(3):e47-9
Abstract
-
Monitoring the emergence of resistance mutations in patients
infected with HIV-1 under salvage therapy
with raltegravir in Rio de Janeiro, Brazil: A follow-up
study.
Passaes CP, Guimarães ML, Cardoso SW,
et
al
J Med Virol. 2012
Dec;84(12):1869-75
Abstract
-
Raltegravir intensification shows differing
effects on CD8 and CD4 T cells in HIV infected
HAART-supressed individuals with poor CD4 T-cell recovery.
Massanella M, Negredo E, Puig J,
et al
AIDS. 2012 Sep 26.
Abstract
-
Changes of cardiovascular biomarkers in
HIV-infected patients switching from ritonavir-boosted
protease inhibitors to raltegravir.
Martinez E, D'lbuquerque PM, Llibre JM, et al
AIDS. 2012 Sep 26
Abstract
-
LDL subclasses and lipoprotein-phospholipase
A2 activity in suppressed HIV-infected patients switching to
raltegravir: Spiral substudy.
Saumoy M, Sánchez-Quesada JL, Martínez E, et a l
Atherosclerosis. 2012 Sep 6.
Abstract
-
Safety and effectiveness of raltegravir in patients with
haemophilia and anti-HIV
multidrug resistance.
Mangiafico L, Perja M, Fusco F,
et al
Haemophilia.
2011 Jul 18.
Abstract
-
A Randomized, Controlled Trial Assessing the Effects of
Raltegravir Intensification on Endothelial Function i
n Treated HIV Infection.
Hatano H, Scherzer R, Wu Y,
et
al
J Acquir Immune Defic Syndr.
2012 Aug 22.
Abstract
-
FULL-TEXT ARTICLE
Switching Virally Suppressed, Treatment-Experienced Patients
to a Raltegravir-Containing Regimen
Does Not Alter Levels of HIV-1 DNA.
Lam YM, McBride KL, Amin J,
et al
PLoS One.
2012;7(3):e31990.
Paper
-
Response to raltegravir-based salvage therapy in HIV-infected patients with
hepatitis C virus or hepatitis B virus coinfection.
Weimer LE, Fragola V, Floridia M, et al
J Antimicrob Chemother.
2012 Sep 14.
Abstract
-
Impaired maraviroc and raltegravir clearance in a human
immunodeficiency virus-infected patient with end-stage liver
disease and renal impairment: a management dilemma.
Pau AK, Penzak SR, Boyd SD, et
al
Pharmacotherapy.
2012 Jan;32(1):
Abstract
-
Acceptable plasma concentrations of raltegravir and etravirine when
administered by gastrostomy tube
in a patient with advanced multidrug-resistant human immunodeficiency
virus infection.
Sandkovsky U, Swindells S, Moore R,
et al
Pharmacotherapy. 2012
Feb;32(2):142-7.
Abstract
-
Mechanisms involved in CD4 gains in HIV-infected
patients switched to raltegravir.
Garrido C, Rallón N, Soriano V,
et al
AIDS. 2011 Dec
29.
Abstract
-
Implications of integrase inhibitors for
HIV-infected transplantation recipients: Raltegravir and
dolutegravir
(S/GSK 1349572).
Waki K, Sugawara Y.
Biosci Trends. 2011
Oct;5(5):189-91.
Abstract
-
Effect of raltegravir intensification on HIV proviral DNA in
the blood and gut mucosa of men on long-term therapy:
a randomized control trial.
Chege D, Kovacs C, La Porte C, et al
AIDS. 2012 Jan
14;26(2):167-74.
Abstract
-
No Effect of Raltegravir Intensification on Viral
Replication Markers in the Blood of
HIV-1-infected Patients Receiving Antiretroviral Therapy.
Gandhi RT, Coombs RW, Chan ES,
et al
J Acquir Immune Defic Syndr.
2011 Nov 11
Abstract
-
Successful tacrolimus treatment following
renal transplant in a HIV-infected patient with raltegravir
previously
treated with a protease inhibitor based regimen.
Cousins D, Topping K, Lee V, et al
Drug Metabol Drug Interact.
2011;26(3):139-41.
Abstract
-
Intensification of Antiretroviral Therapy With
Raltegravir or Addition of Hyperimmune Bovine Colostrum in
HIV-Infected
Patients With Suboptimal CD4+ T-Cell Response: A Randomized Controlled
Trial.
Byakwaga H, Kelly M, Purcell DF, et al
J Infect Dis. 2011
Sep 19.
Abstract
-
Treatment intensification with raltegravir in subjects with
sustained HIV-1 viraemia suppression:
a randomized 48-week study.
Llibre JM, Buzón MJ, Massanella M,
et al
Antivir Ther.
2011 Sep 28.
Abstract
-
A randomized cross-over study to compare raltegravir and efavirenz
(SWITCH-ER study).
Nguyen A, Calmy A, Delhumeau C, et al
AIDS.
2011 May 17
Abstract
-
Switch from Enfuvirtide to Raltegravir Lowers Plasma
Concentrations of Darunavir and Tipranavir:
a pharmacokinetic sub-study of the EASIER-ANRS 138 trial.
Goldwirt L, Braun J, de Castro N, et al
Antimicrob Agents Chemother.
2011 May 16
Abstract
-
Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in
Vertically HIV-Infected Children,
Adolescents
and Young Adults: A 60-Month Follow-Up Study.
Viganò A, Bedogni G, Manfredini V,
et al
Clin Drug Investig.
2011;31(6):407-15
Abstract
-
Raltegravir in patients at high vascular risk.
Olalla J, Del Arco A, de la Torre J,
et al
Med Clin (Barc).
2011 May 9.
Abstract
-
A Randomized, Controlled Trial of Raltegravir Intensification in
Antiretroviral-treated, HIV-infected Patients
with a Suboptimal CD4+ T Cell Response
Hatano H, Hayes TL, Dahl V,
et al
J Infect Dis. 2011
Apr;203(7):960-
Abstract
-
Impact on Health-Related Quality of Life of a Switch From Enfuvirtide
to Raltegravir
Among Multidrug-Resistant HIV-1-Infected Patients: A Randomized
Open-Label Trial
(EASIER-ANRS 138).
Boulet T, Pavie J, Charreau I, Braun J,
et
al
HIV Clin Trials. 2010 Jan
1;11(5):283-293
Abstract
-
HIV-1 Integrase Sequence Variability in Antiretroviral Naïve Patients
and in Triple-Class
Experienced Patients Subsequently Treated with Raltegravir.
Varghese V, Liu TF, Rhee SY,
et al
AIDS Res Hum Retroviruses.
2010 Oct 21
Abstract
-
Clinical, virological and immunological responses in
Danish HIV patients receiving raltegravir
as part of a salvage regimen.
Engsig FN, Gerstoft J, Kronborg G, et al
Clin Epidemiol. 2010 Aug
9;2:145-51
Abstract
-
Effect of raltegravir-containing intensification on HIV burden and
T-cell activation in multiple gut sites of HIV-positive adults on suppressive
antiretroviral therapy.
Yukl SA, Shergill AK, McQuaid K, et al
AIDS. 2010 Sep 4.
Abstract
-
Substitution of raltegravir for ritonavir-boosted protease inhibitors
in HIV-infected patients:
the SPIRAL study.
Martínez E, Larrousse M, Llibre JM, et al
AIDS. 2010 Jul 17;24(11):1697-707
Abstract
-
Prevention of HIV protease inhibitor-induced dysregulation of hepatic
lipid metabolism by
raltegravir via endoplasmic reticulum stress signaling pathways.
Cao R, Hu Y, Wang Y, Gurley EC, et al
J Pharmacol Exp Ther. 2010 Aug;334(2):530-9.
Abstract
-
Minimal removal of raltegravir by hemodialysis in HIV-infected
patients with
end stage renal disease.
Moltó J, Sanz-Moreno J, Valle M, et al
Antimicrob Agents Chemother.
2010 May
Abstract
-
HIV-1 replication and immune dynamics are affected by raltegravir
intensification
of HAART-suppressed subjects.
J Buzón M, Massanella M, Llibre JM, et al
Nat Med.
2010 Mar 14.
Abstract
-
Clinical outcome in resistant HIV-2 infection treated with
raltegravir and maraviroc.
Armstrong-James D, Stebbing J,
Scourfield A, et al
Antiviral Res.
2010 Mar 4.
Abstract
-
Raltegravir, maraviroc, etravirine: an effective protease inhibitor
and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in
HIV-infected patients with triple-class experience.
Nozza S, Galli L, Visco F, Soria A, et al
AIDS. 2010 Feb 11
Abstract
-
Raltegravir-based HAART regimen in a patient with large
B-cell lymphoma.
Fulco PP, Hynicka L, Rackley D.
Ann Pharmacother.
2010 Feb;44(2):377-82.
Abstract
|
-
FULL-TEXT ARTICLE
Usefulness of Integrase resistance testing in proviral HIV-1
DNA in patients with Raltegravir prior failure
Fernández-Caballero JÁ, Chueca N,
et al
BMC Infect Dis.
2016 May 13;16(1):197
Paper
-
Virological failure to raltegravir in Spain: incidence,
prevalence and clinical consequences.
Santos JR, Blanco JL, Masiá M, et al
J Antimicrob Chemother.
2015 Nov;70(11):3087-95
Abstract
-
G118R and F121Y mutations identified in patients failing
raltegravir treatment confer dolutegravir resistance.
Munir S, Thierry
E, Malet I, Subra F,
et al
J Antimicrob Chemother.
2014 Nov 20. pii: dku474.
Abstract
-
FULL-TEXT ARTICLE
HIV-2 Integrase Polymorphisms and
Longitudinal Genotypic Analysis of HIV-2 Infected Patients
Failing a Raltegravir-Containing Regimen.
Cavaco-Silva J, Abecasis A, Miranda AC,et al
PLoS One.
2014 Mar 28;9(3):e92747
Paper
-
HIV-1-infected patients with advanced disease
failing a raltegravir-containing salvage regimen in São
Paulo, Brazil.
de Souza Cavalcanti J, de Paula Ferreira JL, et al
Int J Antimicrob Agents.
2013 Nov 20.
Abstract
-
Three Distinct Phases of HIV-1 RNA Decay in
Treatment-Naive Patients Receiving Raltegravir-Based
Antiretroviral Therapy: ACTG A5248 Study.
Andrade A, Rosenkranz SL, Cillo AR, et al
J Infect Dis. 2013
Jun 24.
Abstract
-
A cohort study of treatment-experienced
HIV-1-infected patients treated with raltegravir: factors
associated with virological response and mutations selected
at failure.
Marcelin AG, Delaugerre C, Beaudoux C, et al
Int J Antimicrob Agents.
2013 Apr 4
Abstract
-
Virological failure at one year in triple-class experienced
patients switching to raltegravir-based regimens
is not predicted by baseline factors.
Bucciardini R, D'Ettorre G, Baroncelli S, Ceccarelli G,
Parruti G, et al
Int J STD AIDS.
2012 Jul;23(7):459-463
Abstract
-
Raltegravir as functional monotherapy leads to virological failure and
drug
resistance in highly treatment-experienced HIV-infected patients.
Caby F, Valin N, Marcelin AG, Schneider L, et al
Scand J Infect Dis.
2010 Mar 12.
Abstract
-
Impaired
maraviroc and raltegravir clearance in a human
immunodeficiency virus-infected patient with
end-stage liver disease and renal impairment: a management
dilemma.
Pau AK, Penzak SR, Boyd SD, et al|
Pharmacotherapy.
2012 Jan;32(1):e1-6.
Abstract
-
Use of novel antiretroviral agents in rescue regimens:
A case of early virological failure to raltegravir.
Tommasi C, Ceccherini-Silberstein F, D'Arrigo R, et al
Scand J Infect Dis.
2010 Jan 19.
Abstract
-
Longitudinal analysis of raltegravir susceptibility and integrase
replication capacity
of HIV-1 during virologic failure.
Fransen S, Karmochkine M, Huang W
Antimicrob Agents Chemother. 2009 Aug 10.
Abstract
|
|
|
Raltegravir Journal Citations |
|
Animal
Studies
HIV/HCV
Indications